Lasa Supergenerics Limited (BOM:540702)

India · Delayed Price · Currency is INR

5.39

0.00 (0.00%)

At close: Oct 5, 2026

Market Cap	266.54M -54.8%
Revenue (ttm)	65.20M -95.2%
Net Income	-165.50M
EPS	-3.30
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,320
Open	5.40
Previous Close	n/a
Day's Range	5.39 - 5.45
52-Week Range	5.39 - 12.46
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Lasa Supergenerics

Lasa Supergenerics Limited engages in the manufacturing API bulk drugs products in India and internationally. It offers API products, such as fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, 2,6-diiodo-4-nitrophenol, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide; and Other API products. The company also provides animal feed ingredients; and reagents for therapeutic use. In addition, it exports its products. Lasa Supergenerics Limited was inc... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2016

Employees 9

Stock Exchange Bombay Stock Exchange

Ticker Symbol 540702

Full Company Profile

Financial Performance

In fiscal year 2026, Lasa Supergenerics's revenue was 252.74 million, a decrease of -82.60% compared to the previous year's 1.45 billion. Losses were -340.90 million, 131.0% more than in 2025.

Financial Statements